Who Owns LifeMD Company?

LifeMD Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns LifeMD?

Understanding a company's ownership is key to grasping its strategic direction and accountability. LifeMD, Inc., a multi-specialty telehealth provider founded in 1994, has evolved significantly since its inception.

As a direct-to-patient telehealth company, LifeMD focuses on accessible remote medical care. Its active patient base grew to 290,000 by Q1 2025, reflecting its expanding reach in the digital health sector. This growth is a testament to its innovative approach.

The ownership landscape of LifeMD is shaped by its founders, institutional investors, and public shareholders. Exploring this structure provides insight into the company's governance and future trajectory. A deeper dive into its market position can be found in the LifeMD PESTEL Analysis.

LifeMD, Inc. was established on May 24, 1994, with Justin Schreiber as its founder. Schreiber has played a pivotal role in the company's trajectory, holding the positions of CEO and Chairman of the board of directors since 2018. Stefan Galluppi is also recognized as a key co-founder.

Founder's Vision

Justin Schreiber, the founder, has been central to the company's development. His leadership as CEO and Chairman guides the ongoing strategy.

Co-Founder's Role

Stefan Galluppi is another significant co-founder of the company. His contributions have been integral to the company's establishment.

Early Ownership Structure

Details on initial equity splits are not widely publicized. However, founders and management retained substantial ownership.

Insider Holdings

As of March 2024, the management team and founders, including Schreiber and Galluppi, collectively held approximately 25% of the company's shares.

Company Evolution

The company's history includes operating under the name Conversion Labs, Inc. This suggests a period of strategic evolution and potential early-stage funding.

Alignment of Interests

The significant insider ownership underscores a commitment to aligning the interests of the board, senior management, and investors.

While specific early equity distributions are not publicly detailed, the substantial ownership by founders and management, amounting to about 25% as of March 2024, indicates a strong co-investment approach. This structure aims to ensure that the company's leadership is deeply invested in its success, mirroring the goals of its broader investor base. The company's prior identity as Conversion Labs, Inc. hints at a foundational period involving strategic development and possibly early investment rounds before its current public trading status, contributing to its overall company history ownership. Understanding this early ownership is key to grasping the LifeMD ownership structure and who owns LifeMD today.

Key Ownership Insights

The founding team and current management maintain a significant stake in the company, reflecting a commitment to its long-term vision.

• Founder: Justin Schreiber
• Co-Founder: Stefan Galluppi
• Insider Ownership (March 2024): Approximately 25%
• Leadership Role: Justin Schreiber serves as CEO and Chairman
• Company History: Previously known as Conversion Labs, Inc.
• Ownership Philosophy: Emphasis on aligning management and investor interests

LifeMD SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

LifeMD, Inc., formerly Conversion Labs, Inc., is a publicly traded entity on the Nasdaq Global Market under the ticker LFMD. Its ownership structure has evolved, reflecting its status as a public company with significant institutional and insider investment. As of August 2025, the company's market capitalization was approximately $297.31 million.

The ownership breakdown of LifeMD reveals a strong presence of institutional investors, who collectively held 57.14% of the company's shares as of August 19, 2025. This represents a notable increase of 29.71% in institutional holdings over the preceding quarter, indicating growing confidence from major financial entities. Key institutional shareholders include BlackRock, Inc., holding 2,655,184 shares, and The Vanguard Group, Inc., with 2,086,122 shares as of June 30, 2025. Other significant institutional stakeholders as of August 2025 include Morgan Stanley, D. E. Shaw & Co., Inc., Nuveen, LLC, State Street Corp, Renaissance Technologies Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, UBS Group AG, Hudson Bay Capital Management LP, BNP Paribas Financial Markets, Canada Pension Plan Investment Board, Qube Research & Technologies Ltd, Jump Financial LLC, and Arrowstreet Capital Limited Partnership. Beyond institutional backing, individual insiders also maintain substantial stakes. Notably, CEO Justin Schreiber owned 2,703,715 shares as of June 2025, representing 5.7% of the company. This significant insider ownership is crucial for aligning management's strategic interests with those of the broader shareholder base, influencing company direction and Revenue Streams & Business Model of LifeMD.

Key LifeMD Shareholders

Institutional investors are the primary owners of LifeMD, with a significant increase in their holdings recently. Insider ownership also plays a vital role in the company's governance.

• BlackRock, Inc.
• The Vanguard Group, Inc.
• CEO Justin Schreiber
• Morgan Stanley
• State Street Corp

LifeMD PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current leadership of LifeMD, Inc. is headed by Justin Schreiber, who has held the positions of Chief Executive Officer and Chairman of the board of directors since 2018. As a co-founder and significant shareholder, Schreiber's influence is deeply intertwined with the company's direction and ownership structure.

LifeMD's corporate governance aligns with the requirements for companies publicly traded on Nasdaq, suggesting adherence to established practices for publicly traded entities. While specific details on voting power mechanisms like dual-class shares are not readily available, the significant institutional ownership, with 235 institutional owners holding over 27 million shares as of August 2025, points to substantial voting influence among these entities. Recent executive appointments in July 2025, including Shayna Webb Dray as COO, Jessica Friedeman as Chief Marketing and Product Officer, and Jacob Ellison as Chief Analytics Officer, indicate a strategic focus on enhancing operational capabilities and refining the company's direction. It is noteworthy that insider selling has occurred, with 275,000 shares sold by insiders in the three months preceding August 2025, without any corresponding insider purchases, a trend that can sometimes be a point of consideration for investors evaluating LifeMD's ownership and management sentiment.

Understanding LifeMD's Shareholding Pattern

The ownership structure of LifeMD is significantly influenced by its institutional investors. These entities collectively hold a substantial portion of the company's shares, indicating their considerable voting power.

• 235 institutional owners as of August 2025
• Over 27 million shares held by institutions
• Justin Schreiber, CEO and Chairman, is a significant shareholder and co-founder
• Recent executive appointments aim to bolster operational efficiency

LifeMD Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, LifeMD's ownership landscape has evolved, marked by a significant increase in institutional investment and some insider divestments. This trend reflects the company's growth and its position within the competitive telehealth sector.

Institutional investors have become increasingly dominant shareholders in LifeMD, with their collective stake reaching 57.14% as of August 2025. This represents a substantial 29.71% increase in institutional shareholdings in the most recent quarter, with prominent entities like BlackRock, Vanguard, and Morgan Stanley notably expanding their positions. For instance, Morgan Stanley saw an 113.571% increase in its holdings, while D. E. Shaw & Co., Inc. reported an 111.836% rise by June 30, 2025. This growing institutional interest suggests a positive outlook from major financial players on the company's future prospects.

Institutional Investment Surge

Institutional ownership has climbed to 57.14% by August 2025. This surge includes significant increases from major firms like Morgan Stanley and D. E. Shaw & Co., Inc.

Insider Selling Activity

In the three months leading up to August 2025, insiders sold 275,000 shares. CEO Justin Schreiber sold 175,000 shares in the six months prior to June 2025.

Strategic Acquisitions and Compensation

The company acquired Optimal Human Health in April 2025 to bolster its presence in the women's health market. A new CEO compensation strategy was implemented in January 2025, setting the annual base salary for Justin Schreiber at $500,000.

Analyst Outlook and Revenue Projections

Analysts maintain a 'Buy' consensus for LFMD stock with an average price target of $12.50. The company projects 2025 consolidated revenue between $268-$275 million, with telehealth revenue expected to grow 32-34%.

LifeMD Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔